Ascentage Pharma Group International ( ($HK:6855) ) has provided an announcement. Ascentage Pharma Group International ...

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced ...

Shares of Ascentage Pharma Group International pared earlier losses to rise 0.75% in the Chinese biopharmaceutical company’s ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

The buzz around biotech IPOs is continuing through January, with clinical-stage metabolic company Aardvark Therapeutics ...

J.P. Morgan and Citigroup acted as joint book-running managers for the offering.

Ascentage Pharma Group (AAPG) (AAPGV) (ASPHF), which is backed by Takeda (TAK), has priced a $126M U.S. initial public offering. Read more here.

Ascentage Pharma’s U.S. IPO will support clinical testing of its two lead drugs, small molecules in development for advanced cases of certain blood cancers. Takeda holds an exclusive option to ...

Ascentage Pharma Group International (Nasdaq: AAPG), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs ...

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

ROCKVILLE, Md. and SUZHOU, China, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (Nasdaq: AAPG) (HKEX: 6855) announced today the closing of its U.S. initial ...